var data={"title":"Eptifibatide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Eptifibatide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6120?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=eptifibatide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Eptifibatide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166052\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Integrilin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166053\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eptifibatide Injection;</li>\n      <li>Integrilin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166082\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166055\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acute coronary syndrome:</b> IV: 180 mcg/kg bolus (maximum: 22.6 mg) administered as soon as possible following diagnosis, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour) until hospital discharge or initiation of CABG surgery (discontinue &ge;2 to 4 hours before surgery (ACCF/AHA [Hillis, 2011]), up to 72 hours. If PCI performed during initial 72 hours, maintain continuous infusion at the time of PCI and continue until hospital discharge or for up to 18 to 24 hours, whichever comes first (total infusion time &le;96 hours). Concurrent aspirin and heparin therapy (target aPTT 50 to 70 seconds) are recommended. <b>Note:</b> If UA/NSTEMI, administration &ge;12 hours before angiography was shown not to be superior to provisional use at the time of PCI and has a higher incidence of bleeding (Giugliano, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Percutaneous coronary intervention (PCI) with or without stenting:</b> IV: 180 mcg/kg bolus (maximum: 22.6 mg) administered immediately before the initiation of PCI, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour). A second 180 mcg/kg bolus (maximum: 22.6 mg) should be administered 10 minutes after the first bolus. Infusion should be continued until hospital discharge or for up to 18 to 24 hours, whichever comes first; shorter infusion durations (ie, &lt;2 hours) may be considered for nonemergent uncomplicated PCI in patients adequately pretreated with clopidogrel (Fung, 2007). Preprocedural aspirin and heparin therapy (ACT 200 to 250 seconds during PCI) and daily aspirin are recommended. Heparin infusion after PCI is discouraged. In patients who undergo CABG surgery, discontinue infusion &ge;2 to 4 hours prior to surgery (ACCF/AHA [Hillis, 2011]). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Primary percutaneous coronary intervention (PCI) during ST-elevation myocardial infarction with or without stenting or pretreatment with clopidogrel (off-label use):</b> IV: Bolus of 180 mcg/kg (maximum: 22.6 mg) administered at the time of PCI, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour) in combination with heparin or bivalirudin. A second 180 mcg/kg bolus (maximum: 22.6 mg) should be administered 10 minutes after the first bolus (ACCF/AHA [O'Gara, 2013]). Infusion was continued for 24 hours in one study (Zeymer, 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166056\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. No dosing adjustment for the elderly appears to be necessary; adjust carefully to renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166057\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The Cockcroft-Gault equation using actual body weight should be used to estimate renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Acute coronary syndrome:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;50 mL/minute: 180 mcg/kg bolus (maximum: 22.6 mg) administered as soon as possible following diagnosis, followed by a continuous infusion of 1 mcg/kg/minute (maximum: 7.5 mg/hour)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ie, dialysis dependent): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Percutaneous coronary intervention (PCI) with or without stenting:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;50 mL/minute: 180 mcg/kg bolus (maximum: 22.6 mg) administered immediately before the initiation of PCI and followed by a continuous infusion of 1 mcg/kg/minute (maximum: 7.5 mg/hour). Administer a second 180 mcg/kg (maximum: 22.6 mg) bolus 10 minutes after the first bolus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ie, dialysis dependent): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable: Yes; ~73 to 83% removed after 1 hour (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15822438\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166033\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Integrilin: 75 mg/100 mL (100 mL); 20 mg/10 mL (10 mL); 200 mg/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg/100 mL (100 mL); 20 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg/100 mL (100 mL); 20 mg/10 mL (10 mL); 200 mg/100 mL (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166018\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166036\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Bolus dose should be withdrawn from the 10 mL vial into a syringe and administered by IV push. Begin continuous infusion (using an IV infusion pump) immediately following bolus administration, administered undiluted directly from the 100 mL vial. The 100 mL vial should be spiked with a vented infusion set.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166034\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute coronary syndrome:</b> Treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction [UA/NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention:</b> Treatment of patients undergoing PCI, including those undergoing intracoronary stenting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25483821\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Primary percutaneous coronary intervention during ST-elevation myocardial infarction; Elective PCI for stable ischemic heart disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174530\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166025\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. Bleeding is the major drug-related adverse effect. Access site is often primary source of bleeding complications. Incidence of bleeding is also related to heparin intensity. Patients weighing &lt;70 kg may have an increased risk of major bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">&gt;10%: Hematologic: &amp; oncologic: Hemorrhage (major: 1% to 11%; minor: 3% to 14%; transfusion required: 2% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (1% to 3%; includes acute profound thrombocytopenia, immune-mediated thrombocytopenia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Anaphylaxis, cerebrovascular accident, gastrointestinal hemorrhage, intracranial hemorrhage, pulmonary hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166039\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to eptifibatide or any component of the formulation; active abnormal bleeding within the previous 30 days or a history of bleeding diathesis; history of stroke within 30 days or a history of hemorrhagic stroke; severe hypertension (systolic blood pressure &gt;200 mm Hg or diastolic blood pressure &gt;110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; current or planned administration of another parenteral GP IIb/IIIa inhibitor; dependency on hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): PT &gt;1.2 times control or INR &ge;2.0; known history of intracranial disease (eg, neoplasm, arteriovenous malformation, aneurysm); severe renal impairment ( CrCl &lt;30 mL/minute); thrombocytopenia (&lt;100,000 cells/mm<sup>3</sup>); clinically significant liver disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166022\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding: The most common complication is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; monitor closely for bleeding, especially the arterial access site for the cardiac catheterization. Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, NSAIDs, and/or P2Y12 inhibitors). Patients &lt;70 kg may be at greater risk for major and minor bleeding. Minimize invasive procedures, including arterial and venous punctures, IM injections, and the use of urinary catheters, nasotracheal intubation and nasogastric tubes. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Hypersensitivity reactions have occurred, including anaphylaxis and urticaria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombocytopenia: Acute, profound thrombocytopenia (immune-mediated and nonimmune mediated) has occurred and may occur within 24 hours of initiation (Cheema, 2006; Coons, 2005; Nagge, 2003; Rezkalla, 2003; Salengro, 2003). Platelet counts should recover rapidly (within 1-5 days) after discontinuation. Use with extreme caution in patients with platelet counts &lt;100,000/mm<sup>3</sup> (contraindicated in the Canadian labeling). If platelet count decreases to &lt;100,000/mm<sup>3</sup> during therapy, discontinue eptifibatide and heparin if administered concurrently. Specific management guidelines for GP IIb/IIIa induced thrombocytopenia have been published (Huxtable, 2006; Llevadot, 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (estimated CrCl &lt;50 mL/minute, using Cockcroft-Gault equation); dosage adjustment required. Use is contraindicated in patients dependent upon hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sheath removal: Prior to pulling the sheath, heparin should be discontinued for 3 to 4 hours and ACT should be &lt;180 seconds or aPTT &lt;50 seconds. Of note, full dose anticoagulation is no longer used after successful PCI procedures (ACCF/AHA/SCAI [Levine, 2011]). Use standard compression techniques after sheath removal. Monitor the site closely afterwards for further bleeding. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgery: Discontinue &ge;2 to 4 hours prior to coronary artery bypass graft surgery (Hillis, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299277\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166027\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8918&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166029\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166041\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20617111\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if eptifibatide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering eptifibatide to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166031\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Coagulation parameters, signs/symptoms of excessive bleeding. Laboratory tests at baseline and monitoring during therapy: hematocrit and hemoglobin, serum creatinine, PT/aPTT (maintain aPTT between 50-70 seconds unless PCI is to be performed), and ACT with PCI (maintain ACT between 200-300 seconds during PCI). Platelet count recommended at 2-4 hours after initiation, and at 24 hours or prior to discharge, whichever is first.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">Assess sheath insertion site and distal pulses of affected leg every 15 minutes for the first hour and then every 1 hour for the next 6 hours. Arterial access site care is important to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through and through) technique for obtaining sheath access. Femoral vein sheath placement should be avoided unless needed. While the vascular sheath is in place, patients should be maintained on complete bedrest with the head of the bed at a 30&deg; angle and the affected limb restrained in a straight position. </p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">Observe patient for mental status changes, hemorrhage, assess nose and mouth mucous membranes, puncture sites for oozing, ecchymosis and hematoma formation, and examine urine, stool and emesis for presence of occult or frank blood; gentle care should be provided when removing dressings.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166021\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor, the binding site for fibrinogen, von Willebrand factor, and other ligands. Inhibition of binding at this final common receptor reversibly blocks platelet aggregation and prevents thrombosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166038\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Immediate after initial bolus (&gt;80% inhibition of ADP-induced aggregation achieved 5 minutes after bolus dose); maximal effect achieved within 1 hour (Gilchrist, 2001; Tardiff, 2001) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Platelet function restored ~4 to 8 hours following discontinuation (Tardiff, 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~25% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~2.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (as eptifibatide and metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Total body: ~55 mL/kg/hour; Renal: ~50% of total body clearance in healthy subjects</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323131\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Eptifibatide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $175.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg/100 mL (100 mL): $564.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $1,624.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Integrilin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $208.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg/100 mL (100 mL): $652.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $1,804.63</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166042\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antigrilin (IN);</li>\n      <li>Integril (BD);</li>\n      <li>Integrilin (AE, AR, AT, AU, BE, BG, BH, CH, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IL, IS, IT, KW, LT, LU, LV, MT, MY, NL, NO, PH, PK, PL, PT, QA, RO, RU, SE, SG, SI, SK, TH, TR, TW);</li>\n      <li>Integrillin (VN);</li>\n      <li>Intehrylin (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20670756\"></a>Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). <i>J Am Coll Cardiol</i>. 2010;56(6):470-475.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/20670756/pubmed\" target=\"_blank\" id=\"20670756\">20670756</a>]</span><span class=\"doi\">10.1016/j.jacc.2009.10.093</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in<i> J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, Giugliano RP, Gibson CM, et al, &ldquo;Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,&rdquo; <i>Circulation</i>, 1999, 99(21):2720-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10351964/pubmed\" target=\"_blank\" id=\"10351964\">10351964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brener SJ, Barr LA, Burchenal JE, et al, &ldquo;Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,&rdquo; ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators, <i>Circulation</i>, 1998, 98(8):734-41.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheema AA, Teklinski AH, Maria V, et al, &ldquo;Recurrent Acute Profound Thrombocytopenia Related to Readministration of Eptifibatide,&rdquo; <i>J Interv Cardiol</i>, 2006, 19(1):99-103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/16483348/pubmed\" target=\"_blank\" id=\"16483348\">16483348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coons JC, Barcelona RA, Freedy T, et al,&ldquo;Eptifibatide-Associated Acute, Profound Thrombocytopenia,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(2):368-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/15644467/pubmed\" target=\"_blank\" id=\"15644467\">15644467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo; <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/23098967/pubmed\" target=\"_blank\" id=\"23098967\">23098967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fung AY, Saw J, Starovoytov A, et al, &ldquo;Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention: The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) Randomized Trial,&rdquo; <i>J Am Coll Cardiol</i>, 2009, 53(10):837-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/19264239/pubmed\" target=\"_blank\" id=\"19264239\">19264239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilchrist IC, O&rsquo;Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. <i>Circulation</i>. 2001;104(4):406-411<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/11468201/pubmed\" target=\"_blank\" id=\"11468201\">11468201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giugliano RP, White JA, Bode C, et al, &ldquo;Early Versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes,&rdquo; <i>N Engl J Med</i>, 2009, 360(21):2176-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/19332455/pubmed\" target=\"_blank\" id=\"19332455\">19332455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamm CW, Heeschen C, Goldmann B, et al, &ldquo;Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,&rdquo; <i>N Engl J Med</i>, 1999, 340(21):1623-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10341274/pubmed\" target=\"_blank\" id=\"10341274\">10341274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huxtable LM, Tafreshi MJ, and Rakkar AN,&ldquo;Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,&rdquo; <i>Am J Cardiol</i>, 2006, 97(3):426-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/16442410 /pubmed\" target=\"_blank\" id=\"16442410 \">16442410 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Inhibition of Platelet Glycoprotein IIb/IIIa With Eptifibatide in Patients With Acute Coronary Syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy,&rdquo; <i>N Engl J Med</i>, 1998, 339(7):436-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9705684/pubmed\" target=\"_blank\" id=\"9705684\">9705684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Integrilin (eptifibatide) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kereiakes DJ, Broderick TM, Roth EM, et al, &ldquo;Time Course, Magnitude, and Consistency of Platelet Inhibition by Abciximab, Tirofiban, or Eptifibatide in Patients With Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention,&rdquo; <i>Am J Cardiol</i>, 1999, 84(4):391-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10468074/pubmed\" target=\"_blank\" id=\"10468074\">10468074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Califf RM, Anderson KM, et al, &ldquo;Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,&rdquo; <i>J Am Coll Cardiol</i>, 1997, 30(1):149-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9207636/pubmed\" target=\"_blank\" id=\"9207636\">9207636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Califf RM, Moliterno DJ, et al, &ldquo;Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,&rdquo; <i>N Engl J Med</i>, 1999, 341(5):319-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10423466/pubmed\" target=\"_blank\" id=\"10423466\">10423466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Tcheng JE, Califf RM, et al, &ldquo;Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,&rdquo; <i>Circulation</i>, 1999, 99(15):1951-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10208997/pubmed\" target=\"_blank\" id=\"10208997\">10208997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Llevadot J, Coulter SA, and Giugliano RP, &quot;A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,&rdquo; <i>J Thromb Thrombolysis</i>, 2000, 9(2):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10613999/pubmed\" target=\"_blank\" id=\"10613999\">10613999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahaffey KW, Harrington RA, Simoons ML, et al, &ldquo;Stroke in Patients With Acute Coronary Syndromes: Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina. Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. The PURSUIT Investigators,&rdquo; <i>Circulation</i>, 1999, 99(18):2371-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10318656/pubmed\" target=\"_blank\" id=\"10318656\">10318656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandak JS, Blankenship JC, Gardner LH, et al, &ldquo;Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis,&rdquo; <i>J Am Coll Cardiol</i>, 1998, 31(7):1518-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9626829/pubmed\" target=\"_blank\" id=\"9626829\">9626829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McClure MW, Berkowitz SD, Sparapani R, et al, &ldquo;Clinical Significance of Thrombocytopenia During a Non-ST-Elevation Acute Coronary Syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience,&rdquo; <i>Circulation</i>, 1999, 99(22):2892-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10359733/pubmed\" target=\"_blank\" id=\"10359733\">10359733</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagge J, Jackevicius C, Dzavik V, et al, &ldquo;Acute Profound Thrombocytopenia Associated With Eptifibatide Therapy,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(3):374-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/12627937/pubmed\" target=\"_blank\" id=\"12627937\">12627937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Randomised Placebo-Controlled Trial of Effect of Eptifibatide on Complications of Percutaneous Coronary Intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II,&rdquo; <i>Lancet</i>, 1997, 349(9063):1422-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9164315/pubmed\" target=\"_blank\" id=\"9164315\">9164315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rezkalla SH, Hayes JJ, Curtis BR, et al, &ldquo;Eptifibatide-Induced Acute Profound Thrombocytopenia Presenting as Refractory Hypotension,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2003, 58(1):76-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/12508202/pubmed\" target=\"_blank\" id=\"12508202\">12508202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salengro E, Mulvihill NT, and Farah B, &ldquo;Acute Profound Thrombocytopenia After Use of Eptifibatide for Coronary Stenting,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2003, 58(1):73-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/12508201/pubmed\" target=\"_blank\" id=\"12508201\">12508201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tardiff BE, Califf RM, Tcheng JE, et al, &ldquo;Clinical Outcomes After Detection of Elevated Cardiac Enzymes in Patients Undergoing Percutaneous Intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(1):88-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9935014/pubmed\" target=\"_blank\" id=\"9935014\">9935014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tardiff BE, Jennings LK, Harrington RA, et al; PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT, <i>Circulation</i>. 2001;104(4):399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/11468200/pubmed\" target=\"_blank\" id=\"11468200\">11468200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topol EJ, Ferguson JJ, Weisman HF, et al, &ldquo;Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta<sub>3</sub> Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,&rdquo; <i>JAMA</i>, 1997, 278(6):479-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9256222/pubmed\" target=\"_blank\" id=\"9256222\">9256222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Merkhof LF, Zijlstra F, Olsson H, et al, &ldquo;Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(6):1528-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10334418/pubmed\" target=\"_blank\" id=\"10334418\">10334418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20670755\"></a>Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. <i>J Am Coll Cardiol</i>. 2010;56(6):463-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/20670755/pubmed\" target=\"_blank\" id=\"20670755\">20670755</a>]</span><span class=\"doi\">10.1016/j.jacc.2009.08.093</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8918 Version 151.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F166052\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F166053\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F166082\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F166055\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F166056\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F166057\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15822438\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F166033\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F166018\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F166036\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F166034\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25483821\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174530\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F166025\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F166039\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F166022\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299277\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F166027\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F166029\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F166041\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20617111\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F166031\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F166021\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F166038\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323131\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F166042\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8918|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=eptifibatide-patient-drug-information\" class=\"drug drug_patient\">Eptifibatide: Patient drug information</a></li></ul></div></div>","javascript":null}